ReviewClinics in liver disease2016
The Progression and Natural History of Pediatric Nonalcoholic Fatty Liver Disease.
Review in Clinics in liver disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 3 syntheses or guidelines pooled it, 165 citations in OpenAlex.
- Global and regional prevalence, burden, and risk factors for MASLD in children and adolescents aged 5 to 24 years: a systematic review, meta-analysis, and modeling study.BMC medicine · 2026Pooled it
- The Green Path to Liver Health: Herbal Solutions for Non-alcoholic Steatohepatitis.Cardiovascular & hematological disorders drug targets · 2025Pooled it
- Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis.World journal of pediatrics : WJP · 2024Pooled it
- Effect of Lactoferrin in Obese Children and Adolescents with Metabolic Dysfunction-Associated Steatotic Disease: A Randomized Controlled Study.Paediatric drugs · 2026Trial
- Outcome of Targeted Therapy for Obstructive Sleep Apnea in Children with Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Children (Basel, Switzerland) · 2026Article
- Risk of complications in adulthood following childhood metabolic dysfunction-associated steatohepatitis based on Korean national health insurance data.Scientific reports · 2026Article
- Hepatopulmonary syndrome as presentation of pediatric metabolic dysfunction-associated steatohepatitis.JPGN reports · 2026Article
- Vibration-controlled transient elastography in pediatric metabolic dysfunction-associated steatotic liver disease.Journal of pediatric gastroenterology and nutrition · 2026Article
- Liver function indicators as risk factors of pediatric metabolic (dysfunction)-associated fatty liver disease: a systematic review and meta-analysis.Translational pediatrics · 2026Article
- The Evolution of Pediatric MAFLD Research (2014-2023): A Decade-Long Bibliometric Analysis of Emerging TrendsEndocrine, metabolic & immune disorders drug targets · 2026Review
- Diagnosis and Management of Pediatric Non-Alcoholic Fatty Liver Disease: An Overview.Metabolites · 2025Review
- Ability of triglyceride-glucose indices to predict metabolic dysfunction associated with steatotic liver disease in pediatric obesity.Journal of pediatric gastroenterology and nutrition · 2025Article
- Longitudinal response to standard of care in pediatric metabolic dysfunction-associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes.Hepatology (Baltimore, Md.) · 2025Article
- Adipose Tissue-Derived Extracellular Vesicle MicroRNAs: Diagnostic Biomarkers for the Pathophysiology Associated with Obesity.Precision chemistry · 2025Review
- Consensus Statement on Metabolic Dysfunction-Associated Steatotic Liver Disease in Children and Adolescents From the Joint TASL-TSPGHAN Expert Committee.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Longitudinal evaluation of pediatric and young adult metabolic dysfunction-associated steatotic liver disease defined by MR elastography.European radiology · 2025Article
- Definition and diagnostic criteria of clinical obesity.The lancet. Diabetes & endocrinology · 2025Review
- M6A methyltransferase METTL3 promotes glucose metabolism hub gene expression and induces metabolic dysfunction-associated steatotic liver disease (MASLD).BMC genomics · 2025Article
- Maternal Western Diet Programmes Bile Acid Dysregulation and Hepatic Fibrosis in Fetal and Juvenile Macaques.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Serum proteome signatures associated with liver steatosis in adolescents with obesity.Journal of endocrinological investigation · 2025Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States. Childhood NAFLD is associated with hepatic and nonhepatic morbidity and mortality. Nonhepatic associations include cardiovascular, metabolic, pulmonary, and psychological disorders. Cardiovascular conditions observed in childhood include left ventricular dysfunction. Furthermore, childhood obesity is associated with greater odds of having hepatocellular carcinoma as an adult. Evidence suggests that NAFLD may begin in utero in children of diabetic mothers. Thus rigorous efforts for structured diagnosis and follow-up are a priority to better develop the understanding of outcomes in pediatric NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.